/ IBRX
/ Market Analysis
ImmunityBio Surges as Anktiva Drives 671% Revenue Growth
IBRX extended its rally after the company posted explosive 671% revenue growth, fueled by rising demand for its bladder cancer drug, Anktiva.
February 25, 2026
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva
ImmunityBio stock surged more than 20% after the European Commission granted conditional approval for its bladder cancer treatment, Anktiva.
February 18, 2026
Why Are IBRX Shares Up in Premarket? FDA Feedback Boosts ANKTIVA
ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label.
January 20, 2026
Why Is ImmunityBio (IBRX) Stock Up Premarket? ANKTIVA Sales Jump 700%
ImmunityBio stock jumped after the company reported preliminary 2025 net product revenue of $113 million, up about 700% year over year.
January 16, 2026
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.
May 13, 2024
Back to 
